South Korean RNA-editing firm enters Eli Lilly’s San Diego innovation hub to speed its precision gene-therapy pipeline toward the clinic. Biotech real estate has its own hierarchy, and San Diego sits near the top. So when a Seongnam-based RNA therapeutics company buys itself a desk inside Eli Lilly’s newest innovation outpost there, it’s worth asking what that access is actually worth and whether it says more about the company or about Lilly’s appetite for outside science. Rznomics Inc announced that it is joining Lilly Gateway Labs (LGL), the pharma giant’s San Diego hub for biotech companies working alongside its scientists and executives [1]. LGL sits under Lilly Catalyze360, the umbrella that also houses Lilly Ventures, Lilly ExploR&D and Lilly TuneLab – Lilly’s answer to the growing pressure on Big Pharma to source innovation externally rather than build it all in-house. The arrangement gives Rznomics wet-lab space and, perhaps more valuably, proximity. Sitting inside the same building as Lilly scientists tends to accelerate the unglamorous parts of drug development: informal conversations, faster feedback loops, introductions that don’t show up in a press release but decide whether a molecule gets a second look. Rznomics says the move will help it accelerate candidate…

Six proteomic clocks detect a younger biological

PRGS&Tech is South Korea’s only team left in X

NRG Therapeutics unpacks the molecular switch be

The preventive-care clinic adds hormone testing,

Rznomics Inc.

Genflow Biosciences PLC reports that its SLAB (Sa

Insilico Medicine published a study in Nature Bio

Licensing deal brings Amprion’s misfolded-prot

Deal with Singapore’s MuseCell Innovations cou

A newly allowed US patent covers the lipid deliv

Fresh off the world’s largest mammalian longev

A new 10–15 minute series aims to bring clarit

iBio will participate in the Wells Fargo 21st Ann

Longeveron will present at the H.C.

eGenesis provided a clinical update from an ongoi

Alkeus announced the publication in JAMA Ophthalm

Mabwell presented Phase Ib/IIa results for its an

One patient spent nine months off dialysis with

VHH brings its ‘village’ model to Malaysia,

Function Health now lets members feed lab result

HCW Biologics received a Notice of Allowance from

HCW Biologics received a Notice of Allowance from

Scribe Therapeutics reported second-quarter 2026

Rapalogix Health has established a dedicated rese

China’s National Medical Products Administratio

FibroBiologics, a Houston-based clinical-stage bi

Mito Health has expanded its direct-to-consumer d

Insilico Medicine, a clinical-stage drug discover

Biotech posts $819.

850 patients signed up for an Alzheimer’s tria

LifespanningRx has launched the Peptide Explorer,

Minicircle was named one of 10 finalists in the s

According to United Therapeutics, the U.S.

USPTO grant strengthens Alterity’s IP position

THPharm already has a drug in late-stage trials.

Exonate Limited has changed its name to Foventa T

NorthStrive Biosciences has executed a First Amen

Resolution Therapeutics has partnered with Blood

Oligomerix appointed Cara Cassino, M.D.

Nature Medicine publication and late-breaking da

Longevity is becoming big business, but the scie

One-year trial results show most patients kept o

Biogen Inc.

Oligomerix has appointed Dr.

NeuroSense has redesigned its PrimeC development

Celularity and MuseCell Innovations have agreed t

NeuroQuant clearance automates amyloid quantific

United Therapeutics will present four oral and fo

LifeVantage reported declines in revenue and earn